Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
  • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
  • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
  • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
  • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
  • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
  • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
  • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
  • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
  • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
  • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
  • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
  • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
  • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
  • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
  • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
  • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/28—Phosphorus compounds with one or more P—C bonds
  • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
  • C07F9/32—Esters thereof
  • C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
  • C07F9/3282—Esters with hydroxyaryl compounds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2602/00—Systems containing two condensed rings
  • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
  • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
  • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

• the present invention provides a method for treating neurodegenerative disorders. More particularly, a method for treating neurodegenerative disorders (e.g., Alzheimer's disease) by inhibiting the interaction of amyloid beta with alpha- 7 nicotinic acetylcholine receptors.
• a method for treating neurodegenerative disorders e.g., Alzheimer's disease
• amyloid beta with alpha- 7 nicotinic acetylcholine receptors.
• AD Alzheimer's disease
• AD Parkinson's disease afflict civilization with great suffering and financial loss.
• AD is characterized by neurofibrillary tangles, neu tic plaques, and neuronal cell death. AD appears as either the familial, early onset ( ⁇ 60 yrs) or late-onset (>60 yrs) forms, with the latter being more prevalent. AD is the major cause of age-related dementia and cognitive impairment
• amyloid precursor protein APP
• ⁇ -amyloid ⁇ -40 and A ⁇ - 2 amyloid precursor protein
• the A ⁇ peptides are derived from APP by proteolytic processing. Dramatic evidence implicating the A ⁇ peptides, particularly A ⁇ 1-42 , in AD comes from various recently identified mutations accounting for certain types of inherited AD. Such mutations in the presenilin (PS1 and PS2) genes are probably the cause of the most frequent form of familial, early-onset AD (Rogaev, E. I. Molecular Biology 1998, 32, 58).
• a ⁇ -42 has a greater ability than A ⁇ 1-40 to aggregate into the amyloid fibrils that constitute the plaques characteristic of AD (Lansbury, P. T., Jr. Accts. Chem. Res. 1996, 29, 317). Even though is generally present to a much larger degree in the cerebrospinal fluid than A ⁇ 1-42 , it is A ⁇ 2 which is the major A ⁇ peptide found in AD plaques.
• the A ⁇ peptides can inhibit cholinergic neurotransmitter function independent of neurotoxicity (Auld, D. S.; Kar, S.; Quirion, R. Trends Neurosci. 1998, 21, 43).
• a ⁇ peptides bind to a number of natural substances such as apoE3, apoE4, apoJ, transthyretin, and albumin.
• a ⁇ has been reported to interact with a membrane-bound receptor for advanced glycation end products and to the class A scavenger receptor (SR) associated with the production of reactive oxygen species. Stimulation of the alpha-7 subtype of the nicotinic acetylcholine receptors (nAChRs) can protect neurons against A ⁇ cytotoxicity (Kihara, T.
• nAChRs are members of the ligand-gated ion channel family and appear to be formed from five protein subunits associating together around a central pore (Lindstrom, J. Molecular Neurobiology 1997 ' , 15, 193). These subunits include ⁇ 1- ⁇ 9, ⁇ 1- ⁇ 4, ⁇ , ⁇ , and ⁇ .
• the ⁇ .7 subtype forms functional homomers which bind to ⁇ - bungarotoxin, a 75-amino acid peptide, with high affinity (0.65-1.7 nM Kd) and nicotine with relatively low affinity (ca. micromolar K d ) (Holladay, M. W.; Dart, M. J.; Lynch, J. K. J. Med. Chem. 1997, 40, 4169).
• Compounds which block the aggregation of A ⁇ peptides are potentially useful drugs for the treatment of AD.
• rifampicin inhibits A ⁇ aggregation and neurotoxicity and may show an effect in vivo in diminishing plaque burden when compared with age-matched controls (Tomiyama, T. et al. J. Biol. Chem. 1996, 277, 6839).
• compounds can be found to either bind to ⁇ 7 nAChRs, to A ⁇ itself, or to both.
• a ⁇ 1-42 to alpha-7 nAChRs provides a seed for crystallization or deposition of A ⁇ into insoluble deposits, which have the potential to grow into the fibrillar amyloid deposits characteristic of AD. Therefore, blocking the interaction of A ⁇ 1- 2 with alpha-7 nAChRs should reduce the amount of insoluble aggregated A ⁇ that is formed, and thus prevent the neurotoxicity and pathology associated with such aggregated amyloid deposits.
• Still another object of the invention is to provide a method for identifying compounds which inhibit the binding of A ⁇ peptides with ⁇ 7 nAChRs, either by binding to A ⁇ peptides or to ⁇ 7 nAChRs.
• the present invention is directed to a method of treating a neurodegenerative disorder in a subject (preferably, a human) in need thereof which comprises administering to the subject an amount of a compound effective to inhibit the binding of an amyloid beta peptide, preferably A ⁇ 1-42 , to alpha-7 nAChRs, preferably, human alpha-7 nAChRs. Since alpha-8 and alpha-9 nAChRs are similar with respect to structure and function to alpha-7 nAChRs, it is possible that blocking the interaction of ⁇ -amyloid with alpha-8 and alpha-9 nAChRs would have therapeutic benefit as well.
• Neurodegenerative disorders included within the methods of the present invention include, but are not limited to, Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), motor neuron diseases including amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease/spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar and pseudobulbar palsy, spinal and spinobulbar muscular atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic
• age-related dementia and other dementias and conditions with memory loss include vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma and diffuse brain damage, dementia pugilistica and frontal lobe dementia.
• vascular dementia diffuse white matter disease
• dementia of endocrine or metabolic origin dementia of head trauma and diffuse brain damage
• dementia pugilistica and frontal lobe dementia dementia pugilistica and frontal lobe dementia.
• other neurodegenerative disorders resulting from cerebral ischemia or infaction including embolic occlusion and thrombotic occlusion as well as intracranial hemorrhage of any type (including, but not limited to, epidural, subdural, subarachnoid and intracerebral), and intracranial and intravertebral lesions (including, but not limited to, contusion, penetration, shear, compression and laceration).
• the neurodegenerative disorder is selected from Alzheimer's disease, Parkinson's disease, Tourette's syndrome, amyotrophic lateral sclerosis, age-related memory loss, senility and age-related dementia, most preferably, the neurodegenerative disorder is Alzheimer's disease.
• the neurodegenerative disorder is Alzheimer's disease, also.defmed as an amyloidosis
• other conditions within the methods of the present invention include other amyloidosis which share features including, but not limited to, hereditary cerebral angiopathy, nonneuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle-Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, and Finnish and Iowa amyloidosis.
• In one embodiment of the invention is a method of treating and/or preventing dementia in an Alzheimer's patient (as well as a method for treating and/or preventing other clinical manifestations of Alzheimer's disease that include, but are not limited to, cognitive and language deficits, apraxias, depression, delusions and other neuropsychiatric symptoms and signs, and movement and gait abnormalities) which comprises administering to the subject a therapeutically effective amount of a compound to inhibit the binding of an amyloid beta peptide (preferably, A ⁇ ! - 42 ) with nAChRs, preferable alpha-7 nAChRs, most preferably, human alpha-7 nAChRs.
• an amyloid beta peptide preferably, A ⁇ ! - 42
• a second embodiment of the invention is a method of improving memory and/or mental status and/or of halting the progression of mental deterioration in an Alzheimer's disease patient which comprises administering to the subject a therapeutically effective amount of a compound to inhibit the binding of an amyloid beta peptide (preferably, A ⁇ - 42 ) with nAChRs, preferably alpha-7 nAChRs, most preferably, human alpha-7 nAChRs.
• an amyloid beta peptide preferably, A ⁇ - 42
• the compound used in the methods of treating neurodegenerative disorders, treating and/or preventing Alzheimer's disease, and improving memory and/or halting the progression of mental deterioration in an Alzheimer's disease patient is not estrogen, raloxifene, droloxifene, tamoxifen, idoxifene or levomeloxifene; more preferably, the compound is not estrogen or a selective estrogen receptor modulator (SERM).
• SERM is an estrogen receptor ligand that exhibits estrogen agonist activity in the cardiovascular system, CNS and bone, and estrogen antagonist activity in reproductive tissues, such as breast and uterus.
• Also included in the invention is the use of a compound which inhibits the binding of an amyloid beta peptide (preferably to an alpha-7 nAChR (preferably, a human alpha-7 nAChR) in the preparation of a medicament for the treatment of a neurodegenerative disorder in a subject (preferably, a human) in need thereof.
• an amyloid beta peptide preferably to an alpha-7 nAChR (preferably, a human alpha-7 nAChR) in the preparation of a medicament for the treatment of a neurodegenerative disorder in a subject (preferably, a human) in need thereof.
• Another illustration of the invention is the use of a compound which inhibits the binding of an amyloid beta peptide (preferably A ⁇ - 2 ) to alpha-7 nAChRs (preferably, human alpha-7 nAChRs) in the preparation of a medicament for: a) improving memory, b) halting the progression of the mental deterioration seen in Alzheimer's disease patients, c) treating dementia, d) preventing dementia in an Alzheimer's patient, and e) treating and/or preventing other clinical manifestations of Alzheimer's disease that include, but are not limited to, cognitive and language deficits, apraxias, depression, delusions and other neuropsychiatric symptoms and signs, and movement and gait abnormalities in an Alzheimer's patient.
• an amyloid beta peptide preferably A ⁇ - 2
• alpha-7 nAChRs preferably, human alpha-7 nAChRs
• Ri is hydrogen or C ⁇ -C 4 alkyl
• R is selected from hydrogen, d-C ⁇ alkyl, aryl or C 7 -C ⁇ 0 aralkyl;
• R3 is selected from hydrogen, C ⁇ -C 6 alkyl, C3-C 10 alkenyl,
• R 2 and R 3 together with the nitrogen to which they are attached, form a five or six-membered heterocyclic ring selected from pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl;
• R is C C 6 alkyl, aryl, or C 7 -C ⁇ 0 aralkyl; and Rsand R 6 are each independently selected from hydrogen, C ⁇ -C 6 alkyl, C3-C10 alkenyl, C ⁇ -C 8 alkylcarbonyl, or diphenylphosphinyl; and pharmaceutically acceptable salts and prodrugs thereof.
• Ri is hydrogen; R 2 is selected from hydrogen or C ⁇ -C 4 alkyl;
• R 3 is selected from C ⁇ -C alkyl, C3-C10 alkenyl, C 5 -C 6 cycloalkylC ⁇ -C4 6 alkyl, d-Ce alkoxycarbonylC ⁇ -C 4 alkyl, C ⁇ -C 6 alkylthio, heteroaryiC ⁇ -C 4 alkyl, or unsubstituted or substituted C 7 -C ⁇ o aralkyl wherein the substituent on the aralkyl are one or two substituents independently selected from the group consisting of halogen, hydroxy, C ⁇ -C 4 alkyl and unsubstituted or substituted C ⁇ -C alkoxy wherein the substituents on the alkoxy are one or two substituents independently selected from amino, C ⁇ -C alkylamino, C ⁇ -C 4 dialkylamino, pyrrolidinyl, or piperidinyl; or
• R 4 is C ⁇ -C 4 alkyl
• R 5 and R 6 are each independently selected from hydrogen, C 1 -C alkyl, C 3 -C 6 alkenyl, C ⁇ -C 6 alkylcarbonyl, or diphenylphosphinyl.
• Ri is hydrogen or C-i-C 4 alkyl
• R 2 and R 3 are each independently selected from hydrogen, Ci-Ce alkyl, aryl or C 7 -C ⁇ o aralkyl; and l ⁇ is C ⁇ -C 6 alkyl, aryl, or C7-C10 aralkyl; and pharmaceutically acceptable salts thereof.
• Compounds of formula I are novel compounds which block the interaction of beta-amyloid with alpha-7 nAChRs. More specifically, the compounds of formula I inhibit the binding of human alpha-7 nAChRs by binding to A ⁇ -42 .
• the orientation between the nitrogen atom and R. 1 on the appropriate ring can be either cis or trans.
• the compound is 5,8-dihydroxy-frans-2-di( ⁇ /-propylamino)-3-methyl-1 ,2,3,4- tetrahydronaphthalene, and pharmaceutically acceptable salts thereof.
• Other compounds useful in the methods of the present invention inhibit the binding of A ⁇ - 42 with human alpha-7 nAChRs by binding to human alpha- 7 nAChRs directly.
• An example of such a compound which binds to human alpha-7 nAChRs is ⁇ -bungarotoxin .
• the present invention provides methods of treating neurodegenerative disorders by inhibiting the binding of amyloid beta peptides to alpha-7 nAChRs.
• Neurodegenerative disorders included within the methods of the present invention include, but are not limited to, Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), motor neuron diseases including amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease/spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar
• age-related dementia and other dementias and conditions with memory loss include vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma and diffuse brain damage, dementia pugilistica and frontal lobe dementia.
• vascular dementia diffuse white matter disease
• dementia of endocrine or metabolic origin dementia of head trauma and diffuse brain damage
• dementia pugilistica and frontal lobe dementia dementia pugilistica and frontal lobe dementia.
• other neurodegenerative disorders resulting from cerebral ischemia or infaction including embolic occlusion and thrombotic occlusion as well as intracranial hemorrhage of any type (including, but not limited to, epidural, subdural, subarachnoid and intracerebral), and intracranial and intravertebral lesions (including, but not limited to, contusion, penetration, shear, compression and laceration).
• the neurodegenerative disorder is selected from Alzheimer's disease, Parkinson's disease, Tourette's syndrome, amyotrophic lateral sclerosis, age-related memory loss, senility and age-related dementia, most preferably, the neurodegenerative disorder is Alzheimer's disease. Because, most preferably, the neurodegenerative disorder is Alzheimer's disease, also .
• amyloidosis other conditions within the methods of the present invention include other amyloidosis which share features including, but not limited to, hereditary cerebral angiopathy, nonneuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle-Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, and Finnish and Iowa amyloidosis.
• amyloid beta refers to amyloid beta peptides and include the A ⁇ -4 0 , peptides and their fragments.
• fragments of amyloid beta peptides include, but not limited to, fragment 1-28, and fragment 25-35 (e.g., Yatin SM, Aksenov M, Butterfield DA. Neurochem Res 1999 Mar;24(3):427-35; Hirakura Y, Satoh Y, Hirashima N, Suzuki T, Kagan BL, Kirino Y.
• subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
• terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
• alkyl shall mean straight or branched chain alkanes of one to ten carbon atoms, or any number within this range.
• alkyl radicals include, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl and 2-methylpentyl.
• Alkoxy radicals are oxygen ethers formed from the previously described straight or branched chain alkyl groups.
• Cycloalkyl groups contain 3 to 8 ring carbons and preferably 5 to 7 carbons.
• alkenyl and alkynyi groups include straight and branched chain alkenes and aikynes having 2 to 10 carbon atoms, or any number within this range.
• aryl indicates aromatic groups such as phenyl and naphthyl.
• C7-C10 aralkyl means an alkyl group substituted with an aryl group wherein the total number of carbon atoms is between 7 and 10 (e.g., benzyl, phenylethyl, phenylpropyl).
• heteroaryl represents an unsubstituted or substituted stable five or six membered monocyclic aromatic ring system or an unsubstituted or substituted nine or ten membered benzo-fused heteroaromatic ring system or bicyclic heteroaromatic ring system which consists of carbon atoms and from one to four heteroatoms selected from N, O or S, and wherein the nitrogen or sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
• the heteroaryl group may be attached at any heteroatom or carbon atom that results in the creation of a stable structure.
• heteroaryl groups include, but are not limited to pyridyl, pyridazinyl, thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, indolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl adeninyl or quinolinyl.
• Prefered heteroaryl groups include pyridyl, pyrrolyl, pyrazinyl, thiadiazolyl, pyrazolyl, thienyl, triazolyl and quinolinyl.
• N(CH 2 ) 5 means a piperidinyl group.
• cC 6 Hn refers to a cyclohexyl group.
• substituted e.g., aryl, aralkyl
• that group may have one or more substituents, preferably from one to five substituents, more preferably from one to three substituents, most preferably from one to two substituents, independently selected from the list of substituents.
• a "phenyld-C 6 alkylamidoC ⁇ -C 6 alkyl" substituent refers to a group of the formula
• Compounds which are useful in the methods of the present invention for inhibiting the interaction of A ⁇ -40 and A ⁇ -42 to the alpha-7 subtype of nAChRs for either the purpose of direct therapeutic intervention or in order to screen for compounds which act via this mechanism include compounds of formula I, especially 5, 8-dihydroxy-fra/?s-2-di( ⁇ /-propylamino)-3-methyl-1 , 2,3,4- tetrahydronaphthalene (Compound 9), (-)-nicotine, (rac)-epibatidine, ⁇ - bungarotoxin, and pharmaceutically acceptable salts thereof.
• Certain peptide stretches of the human alpha-7 nAChR bind to amyloid beta and can be used in place of the alpha-7 nAChR together with amyloid beta for the purpose of screening libraries to find compounds which block the interaction of amyloid beta and the human alpha-7 nAChR. Included among these peptide stretches of the human alpha-7 nAChR are alpha-7 nAChRI 93- 224 and smaller peptides derived thereof as listed in the Table. Table
• the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts.”
• Other salts may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts.
• Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
• suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
• alkali metal salts e.g., sodium or potassium salts
• alkaline earth metal salts e.g., calcium or magnesium salts
• suitable organic ligands e.g., quaternary ammonium salts.
• the present invention includes within its scope prodrugs of the compounds of this invention.
• a prodrug is inactive as administered, but becomes activated in vivo.
• the prodrug is converted to the parent drug chemically or by specific enzyme(s).
• prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the required compound.
• the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
• Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
• the compounds according to this invention may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
• (-)-Nicotine is (-)-1-methyl-2-(3-pyridinyl)pyrrolidine and is readily available from Sigma Chemical Company.
• (+/-)-Epibatidine is exo-(+/-)-2-(6-chloro-3-pyridinyl)-7- azabicyclo[2.2.1]heptane and is readily available from Sigma Chemical Company.
• ⁇ -Bungarotoxin is a 74 amino acid peptide which is commercially available from Research Biochemicals Inc. ⁇ -Bungarotoxin and its amino acid sequence are described in Lee, C. Y. Annu. Rev. Pharmacol. 1972, 12, 265- 281.
• 125, -A ⁇ - 0 , and anti-alpha-7 nAChR antibodies are commercially available Amersham Pharmacia Biotech, Advanced Bioconcepts and Research Biochemicals International, respectively.
• 125 l- ⁇ -bungarotoxin is commercially available from Amersham Pharmacia Biotech.
• the present invention therefore provides a method of treating a neurodegenerative disorder, which comprises administering any of the compounds as defined herein in a quantity effective to treat the neurodegenerative disorder.
• the compound is not estrogen, raloxifene, droloxifene, tamoxifen, idoxifene or levomeloxifene; more preferably, the compound is not estrogen or a selective estrogen receptor modulator (SERM).
• SERM selective estrogen receptor modulator
• the compound may be administered to a patient afflicted with a neurodegenerative disorder by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal, buccal, intracerebral and other parenteral routes.
• the quantity of the compound which is effective for treating a neurodegenerative disorder is between 0.01 mg per kg and 10 mg per kg of subject body weight.
• the method of treating neurodegenerative disorders described in the present invention may also be carried out using a pharmaceutical composition
• a pharmaceutical composition comprising any of the compounds as defined herein and a pharmaceutically acceptable carrier.
• the pharmaceutical composition may contain between about 0.5 mg and 200 mg of the compound, and may be constituted into any form suitable for the mode of administration selected.
• Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
• Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, caplets, and powders, and liquid forms, such as solutions, syrups, elixers, and suspensions.
• Forms useful for intracerebral and other parenteral routes of administration include sterile solutions, emulsions and suspensions.
• Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient age, body weight, diet, physical activity and time of administration, and associated co-morbidities and clinical conditions will result in the need to adjust dosages.
• the present invention also provides diagnostic tools useful for diagnosing Alzheimer's disease.
• Alzheimer's disease exhibits neuropathological abnormalities in the olfactory system located in the nasal cavity. These include the presence of dystrophic neurites that exhibit immunoreactivity for tau, neurofilaments, apolipoprotein E and other proteins, abnormal tau protein, increase in superoxide dismutase, and beta-amyloid deposition in the primary sensory (olfactory receptor) cells and nerve fibres of the nasal mucosa tissue (Arnold et al., Ann N Y Acad Sci 1998 Nov 30;855:762-75; Hock et al., Eur Neurol 1998 Jul;40(1):31-6; Johnson et al., Neurobiol Aging 1994 Nov- Dec;15(6):675-80; Kulkami-Narla et al., Exp Neurol 1996 Aug; 140(2): 115-25; Lee et al., Exp Neurol 1993 May;121(1 ):93-105; Tabat
• AD patients e.g., central nervous system neurons from AD patients.
• Routine access to these sensory neurons and fibers can be done with nasal biopsy in AD patients (e.g., Feron et al., Arch Otolaryngol Head Neck Surg 1998 Aug;124(8):861-6).
• Olfactory neuroblasts olfactory neurons obtained by biopsy and placed in primary cell culture
• AD patients produce carboxy terminal amyloid precursor protein (APP) fragments that contain beta-amyloid (A-beta)(Crino et al., Ann Otol Rhinol Laryngol 1995 Aug;104(8):655-61).
• Crino et al. showed labeling of A-beta in the basal third of the olfactory neuroepithelium and in axons projecting through the lamina intestinal of AD patients.
• Thioflavin-S staining that detects amyloid deposition was also observed in the basal third of the olfactory neuroepithelium from AD patients.
• Alpha 7 nicotinic acetylcholine receptors are present in olfactory neurons probably including olfactory receptor cells in the nasal cavity (Alkondon et al., Neurosci Lett 1994 Aug 1;176(2): 152- 6; Alkondon et al., Eur J Neurosci 1997 Dec;9(12):2734-42; Bouvet et al., Neurosci Res 1988 Feb;5(3):214-23; Edwards et al., Experientia 1987 Aug 15;43(8):868-73; Edwards et al., Experientia 1988 Mar 15;44(3):208-11; Seguela et al., J Neurosci 1993 Feb;13(2):596-604).
• Beta-amyloid peptide increases cytosolic-free Ca 2+ in AD lymphoblasts (Ibarreta et al., Alzheimer Dis Assoc Disord 1997 Dec;11(4):220-7), and elevates mitogen-induced Ca 2+ responses in freshly prepared human lymphocytes (Eckert et al., Life Sci 1994;55(25-26):2019-29).
• Amyloid precursor protein can be induced on the cell surface of human lymphocytes upon stimulation (Bullido et al., Biochim Biophys Acta 1996 Aug 21 ;1313(1 ):54-62) and increased APP-770 isoform occurs in lymphocytes from AD patients (Ebstein et al., Brain Res Mol Brain Res 1996 Jan;35(1-2):260-8). Lymphoblastoid cells from patients with early-onset and late-onset familial AD show increased expression of beta-APP mRNA and protein (Matsumoto et al., Eur J Biochem 1993 Oct 1 ;217(1 ):21-7). Lymphocytes from AD patients also exhibit an increased mRNA level for alpha 7 nicotinic receptor (Hellstrom- Lindahl et al., Brain Res Mol Brain Res 1999 Mar 20;66(1-2):94-103)
• AD alpha 7 nicotinic acetylcholine receptor - beta amyloid peptides interaction in circulating blood cells and olfactory neuroepithelial neurons/neuronal processes or olfactory neuroblasts obtained from AD patients could be used as AD diagnostic tools, markers of AD progression and prognosis, and markers of therapeutic efficacy for any intervention or treatment targeting AD.
• the present invention provides methods for diagnosing
• Alzheimer's disease monitoring the progression and prognosis of Alzheimer's disease and/or monitoring the therapeutic efficacy of any intervention or treatment of Alzheimer's disease comprising:
• test sample comprises circulating blood cells and/or olfactory neuroepithelial neuronal cell bodies or their neuronal processes (i.e., dendrites and axon of a nueron); and
• amyloid beta peptide including, but not limited to, A ⁇ 1-40 , A ⁇ 1-42 and A ⁇ - 3 peptides and their fragments
• alpha-7 nicotinic acetylcholine receptors alpha-7 nicotinic acetylcholine receptors
• BSA bovine serum albumin
• nAChR nicotinic acetylcholine receptor
• Ph phenyl
• PCC pyridinium chlorochromate TEA triethyl amine THF tetrahydrofuran TLC thin layer chromatography
• This material can then be subjected to a reductive amination reaction such as with propionaldehyde as shown to yield (8).
• Compound (8) is then treated with HBr in acetic acid to cleave the methyl ethers and form dihydroxy compound (9).
• BBr 3 may be used to cleave the methyl ethers and form dihydroxy compound (9).
• a deficiency of BBr 3 may be used to provide compounds in which only one of the methyl ethers has been removed to afford compounds with one hydroxy and one methoxy group.
• a further means of preparing compounds of the present invention is illustrated in Scheme 2.
• This material is then subjected to an aminomercuration reaction to afford a 2- amino-1 ,4-butadiene such as compound (12).
• Diels-Alder reaction of compound (12) with benzophenone (1) gives (13) which can be isomerized as in Scheme 1 with base to give the 1 ,5-dihyroxy compound (14).
• Compounds of type 9 can be treated with a base such as triethylamine in a suitable solvent such as dioxane or methylene chloride along with electrophiles such as acid halides, phosphinyl halides, or alkyl halides to give the products of substitution on one or both of the phenolic hydroxyls.
• a base such as triethylamine
• a suitable solvent such as dioxane or methylene chloride
• electrophiles such as acid halides, phosphinyl halides, or alkyl halides
• Fraction 1 (0.306g, 1.0 mmol) and fumaric acid (0.141 g, 1.2 mmol) were dissolved in ethanol (2 mL) with heating. The ethanol was evaporated and the residue triturated with diethyl ether affording the fumarate salt of 18 as a white solid. Similarly obtained from Fraction 2 (0.301 g, 1.0 mmol) and fumaric acid (0.141 g, 1.2 mmol) was the fumarate sale of 17.
• Ketone 6 (0.299 g, 1.36 mmol) was dissolved in toluene (1 mL) followed by the addition of morphoiine (0.130 g, 0.13 mL, 1.5 mmol) and Ti(/-PrO) (0.611 g, 0.64 mL, 2.15 mmol). The reaction mixture was stirred for 15 hrs at room temperature. Methanol (2 mL) was added followed by portionwise addition of NaBH 4 (0.15 g, 3.9 mmol) over 1 hr. Dichloromethane and 1N
• Ketone 6 (1 g, 4.5 mmol) was dissolved in acetonitrile (75 mL) followed by the addition of acetic acid (0.54 mL, 9 mmol, 2 eq.) and propargylamine (0.6 mL, 9 mmol, 2 eq.). The reaction mixture was stirred at room temperature for 1 hr. Sodium cyanoborohydride (0.6 g, 9 mmol, 2 eq.) was added portionwise (3x) over 1.5 hrs (every 30 min), and the reaction mixture was stirred overnight at room temperature. Ethyl acetate and 1 N NaOH were added with thorough mixing and the organic layer was separated, dried with MgS0 4 , filtered and evaporated to an oil.
• acetic acid (0.54 mL, 9 mmol, 2 eq.
• propargylamine 0.6 mL, 9 mmol, 2 eq.
• the product was purified with flash chromatography (50:50/ethyl acetate:hexane) to yieid an oil of 5,8-dimethoxy-c/s and trans-2-N- (propargyl)amino-3-methyl-1 ,2,3,4-tetrahydronaphthalene (1.2 g, 100%).
• This material was dissolved in acetonitrile along with propionaldehyde (0.65 g, 9 mmol, 2 eq.) and acetic acid (0.5 mL, 9 mmol) and stirring for 1 hr at room temperature.
• Example 11 As a specific embodiment of an oral composition, 100 mg of Compound 9 from Example 1 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
• 100 mg of Compound 9 from Example 1 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
• Example 11
• a ⁇ 1-42 and A ⁇ _4 0 binding to alpha-7 nAChRs can be demonstrated in competitive binding experiments with ⁇ -bungarotoxin
• SK-N-MC cell membranes were incubated with 0.5 nM of 125 l- ⁇ - bungarotoxin in the presence of various concentrations of A ⁇ _ 2 and A ⁇ 1-40 at 25°C for 1 hr. The assay mixture was then rapidly filtered and the radioactivity that was retained on the filter was determined.
• a ⁇ 1- 2 binding to alpha-7 nAChRs is supported by competitive binding experiments with 125 I-A ⁇ _ 40 and provides a seed for amyloid deposition and, thus, incipient plaque formation
• Alpha-7 nAChRs were immobilized on wheat germ agglutinin coupled yittrium SPA beads and allowed to incubate with 125 l-A ⁇ 1-40 in the presence of various concentrations of cold A ⁇ or A ⁇ 1-42 .
• the data showed that 0.1 femtoM of cold A ⁇ - 42 completely abolished the binding, suggesting that A ⁇ -42 interacted with alpha-7 nAChRs with high affinity.
• 10 nM of cold to alpha-7 nAChRs was dramatically increased.
• a ⁇ _42 binding to alpha-7 nAChRs is of higher affinity than A ⁇ o binding to alpha-7 nAChRs
• Alpha-7 nAChRs were allowed to interact with or A ⁇ 1-42 and the mixture was then immunoprecipitated with anti-alpha-7 nAChR antibodies.
• Western analyses of the immunoprecipitated proteins identified only the presence of A ⁇ 1-42 , indicating that the A ⁇ 1- 2 /alpha-7 nAChR interaction is robust and of high affinity. Since it has already been shown that A ⁇ 1-40 binds to the alpha-7 receptor, the failure in detecting in this co-precipitation experiment suggests that the A ⁇ 1- 0 /alpha-7 nAChR interaction is of lower affinity than the A ⁇ 1-42 /alpha-7 nAChR interaction.
• a ⁇ s are known to form aggregates leading to the formation of amyloid plaques that are characteristic of Alzheimer's disease. This phenomenon can be demonstrated in vitro by using Synthaloid plates, coated with A ⁇ crystallization centers, and labelled A ⁇ s for detecting aggregation. We have validated this aggregation assay using both 125 l-A ⁇ 1-40 and in a buffer containing 50 mM HEPES, pH 7.4, 0.1% BSA, 10% FCS and protease inhibitors.
• Compounds which inhibit A ⁇ aggregation with an IC 50 ⁇ 100 micromolar may be effective in inhibiting the binding of A ⁇ to alpha-7 in such a manner as to have a positive therapeutic effect useful for the treatment of neurodegenerative disorders.
• Synaptosomes from guinea pig hippocampus were incubated with 0.1 ⁇ M 3 H-choline and then subjected to repeated washes to remove unincorporated 3 H-choline.
• the synaptosomes were treated with 65 mM K + for 30 seconds to elicit 3H-acetylcholine release. While A ⁇ o and A ⁇ z at 100 pM both inhibited acetylcholine release from these preparations (33% inhibition for both A ⁇ - 0 and A ⁇ - 42 ) .
• pretreatment of the synaptosomes with both 10 nM of Compound 9 and 100 pM of either stimulation was found to have no effect on acetylcholine release.
• alpha-7 nAChR contained SK-N-MC cell membranes were immobilized on wheat germ agglutinin coupled yittrium SPA beads and allowed to incubate with 25 l-A ⁇ 1-40 in the presence of various concentrations of compound 9.
• the result demonstrated that Compound 9 efficiently inhibited the binding of 125 l- SK-N-MC cells with a 300 pM IC50.
• Compounds which inhibit the binding of A ⁇ to alpha-7 nAChRs with an IC50 ⁇ 1 micromolar may have a positive therapeutic effect useful for the treatment of neurodegenerative disorders.
• a 2-5 ug quantity of the 11 amino acid peptide comprised of the 206- 216 stretch of the ⁇ 7 nAChR (N-Ac, C(O)NH 2 ) are added to a 96-well microtiter plate in 50 mL 10mM HEPES, pH 7.4, or any buffer 50ul.
• 125 l- ⁇ -amyloidi-40 (2000Ci/mmol, 50pM) was added to the wells in the presence and absence of inhibitors (1 uM to 10 uM) dissolved in 1uL of 30% or 100% DMSO. Unbound ligands were removed and bound radioactivity was measured using a Microbeta liquid scintillation counter. Ligand binding can be inhibited by ⁇ - bungarotoxin, the peptide itself, and Compound 9.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Neurology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Physical Education & Sports Medicine (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Psychology (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Immunology (AREA)
• Hospice & Palliative Care (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Rheumatology (AREA)
• Urology & Nephrology (AREA)
• Psychiatry (AREA)
• Heart & Thoracic Surgery (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22206004

Family Applications (1)

Country Status (12)

Cited By (36)

Families Citing this family (39)

Family Cites Families (6)

• 1999
  • 1999-05-27 EP EP99928342A patent/EP1083889B1/en not_active Expired - Lifetime
  • 1999-05-27 JP JP2000551761A patent/JP4637351B2/ja not_active Expired - Fee Related
  • 1999-05-27 DK DK99928342T patent/DK1083889T3/da active
  • 1999-05-27 ES ES99928342T patent/ES2212570T3/es not_active Expired - Lifetime
  • 1999-05-27 AT AT99928342T patent/ATE255888T1/de active
  • 1999-05-27 AU AU45433/99A patent/AU765142B2/en not_active Expired
  • 1999-05-27 DE DE69913520T patent/DE69913520T2/de not_active Expired - Lifetime
  • 1999-05-27 CA CA2333951A patent/CA2333951C/en not_active Expired - Lifetime
  • 1999-05-27 US US09/320,885 patent/US6441049B2/en not_active Expired - Lifetime
  • 1999-05-27 WO PCT/US1999/011702 patent/WO1999062505A2/en not_active Ceased
  • 1999-05-27 PT PT99928342T patent/PT1083889E/pt unknown
  • 1999-06-01 AR ARP990102580A patent/AR018431A1/es unknown
• 2002
  • 2002-06-05 US US10/162,821 patent/US7018797B2/en not_active Expired - Lifetime

Also Published As

Similar Documents

Legal Events